Evidence map›Paper›PMID 32366854›Full record

ArticleScientific reports2020

Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice.

Muhammed Majeed, Shaheen Majeed, Kalyanam Nagabhushanam, Lincy Lawrence, Lakshmi Mundkur

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Muhammed MajeedSami Labs Limited, Peenya Industrial Area, Bangalore, 560 058, Karnataka, India.
Shaheen MajeedSabinsa Corporation, 750 Innovation Circle, Payson, UT, 84651, USA.ORCID http://orcid.org/0000-0001-6400-8245
Kalyanam NagabhushanamSabinsa Corporation, 20 Lake Drive, East, Windsor, NJ, 08520, USA.ORCID http://orcid.org/0000-0001-9470-4110
Lincy LawrenceSami Labs Limited, Peenya Industrial Area, Bangalore, 560 058, Karnataka, India.
Lakshmi MundkurSami Labs Limited, Peenya Industrial Area, Bangalore, 560 058, Karnataka, India. lakshmi@samilabs.com.ORCID http://orcid.org/0000-0003-2928-1726
Sami Labs (India) · INSabin Vaccine Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic steatohepatitis (NASH) is a progressive form of Non-alcoholic fatty liver disease (NAFLD), a chronic liver disease with a significant unmet clinical need. In this study, we examined the protective effects of Garcinia indica extract standardized to contain 20% w/w of Garcinol (GIE) and 95% Curcuminoids w/w from Curcuma longa (Curcuminoids) in a Stelic animal model (STAM) of NASH. The STAM mice developed steatosis, hepatocyte ballooning, and inflammation, which were significantly reduced by the combination of GIE and Curcuminoids, resulting in a lower NAFLD activity score. The treatment reduced fibrosis as observed by Sirius red staining, liver hydroxyproline content and mRNA levels of TGF- β and collagen in the liver. Immunostaining with alpha-smooth muscle actin (α SMA) revealed a significant reduction in hepatic stellate cells. Intriguingly, the combination regimen markedly decreased the mRNA levels of MCP1 and CRP and both mRNA and protein levels of TNF-α. NF-kB, reduced the hepatic and circulating FGF21 levels and altered the nonenzymatic (glutathione) and enzymatic antioxidant markers (Glutathione peroxidase, and superoxide dismutase). Our results suggest that the combination of GIE and Curcuminoids can reduce the severity of NASH by reducing steatosis, fibrosis, oxidative stress, and inflammation. The results suggest that the combinatorial regimen could be an effective supplement to prevent the progression of liver steatosis to inflammation and fibrosis in NASH.

Indexed as

ActinsAnimalsAntioxidantsDiarylheptanoidsDisease Models, AnimalDisease ProgressionDrug Therapy, CombinationFatty LiverFemaleFibrosisGlutathioneHepatic Stellate CellsHep G2 CellsHumansInflammationLiverActinsAntioxidantsDiarylheptanoidsgarcinolGlutathioneMalondialdehydeSuperoxide DismutaseTerpenesTriglycerides

Identifiers

PMID32366854
PMCPMC7198554
OpenAlexW3023088542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.